{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Microdosing",
    "query": {
      "condition": "Microdosing"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 26,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Microdosing&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T18:34:37.644Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01266096",
      "title": "PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Newly Diagnosed or Recurrent Metastatic Melanoma Patients",
        "Malignant Brain Tumors"
      ],
      "interventions": [
        {
          "name": "PET scan with 124I-cRGDY-PEG-dots",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2011-01",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-07-22T18:34:37.644Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01266096"
    },
    {
      "nct_id": "NCT03465618",
      "title": "A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Cancer",
        "Pituitary Adenoma"
      ],
      "interventions": [
        {
          "name": "89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging",
          "type": "DRUG"
        },
        {
          "name": "Blood and Urine samples",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2018-03-07",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-07-22T18:34:37.644Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03465618"
    },
    {
      "nct_id": "NCT06254833",
      "title": "Microdosing ICG for Serial Colonic Perfusion Study During Surgery",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Perfusion; Complications"
      ],
      "interventions": [
        {
          "name": "micro dosing of ICG",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Shanglei Liu",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2023-11-01",
      "completion_date": "2024-11-01",
      "has_results": false,
      "last_update_posted_date": "2024-02-12",
      "last_synced_at": "2026-07-22T18:34:37.644Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06254833"
    },
    {
      "nct_id": "NCT07449351",
      "title": "Psilocybin Microdosing on Cognition, Mood and Quality of Life",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI"
      ],
      "interventions": [
        {
          "name": "Psliocybin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "21 Years to 40 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-08-10",
      "completion_date": "2028-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-07-22T18:34:37.644Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07449351"
    },
    {
      "nct_id": "NCT07325500",
      "title": "Incretin Microdosing for Cardiometabolic Health in People With HIV",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Weight Gain"
      ],
      "interventions": [
        {
          "name": "Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly",
          "type": "DRUG"
        },
        {
          "name": "Dose escalation to 2 mg semaglutide weekly then no semaglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-02-12",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-07-22T18:34:37.644Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07325500"
    },
    {
      "nct_id": "NCT03350256",
      "title": "BurstDR™ micrOdosing stimuLation in De-novo Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pain, Intractable",
        "Pain, Back"
      ],
      "interventions": [
        {
          "name": "Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Abbott Medical Devices",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2017-10-30",
      "completion_date": "2019-07-02",
      "has_results": true,
      "last_update_posted_date": "2020-03-19",
      "last_synced_at": "2026-07-22T18:34:37.644Z",
      "location_count": 5,
      "location_summary": "Santa Rosa, California • Reno, Nevada • Asheville, North Carolina + 2 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        },
        {
          "city": "Asheville",
          "state": "North Carolina"
        },
        {
          "city": "Killeen",
          "state": "Texas"
        },
        {
          "city": "Charleston",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03350256"
    },
    {
      "nct_id": "NCT06366451",
      "title": "PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Rilvegostomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Volrustomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sabestomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD9592",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD9592 + Rilvegostomig",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AZD9592 + Volrustomig",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AZD9592 + Sabestomig",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AZD9592 + Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Presage Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2024-05-22",
      "completion_date": "2026-03-25",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-07-22T18:34:37.644Z",
      "location_count": 7,
      "location_summary": "Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 3 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06366451"
    },
    {
      "nct_id": "NCT07588984",
      "title": "GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obesity & Overweight",
        "Weight Loss",
        "Preventative Health",
        "Body Weight",
        "Cardiovascular Disease Risk Factor"
      ],
      "interventions": [
        {
          "name": "Noom Weight",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Free Tier",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Education-only control",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Microdose semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Microdose tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "Noom Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 2310,
      "start_date": "2026-04-30",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-07-22T18:34:37.644Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07588984"
    },
    {
      "nct_id": "NCT03056599",
      "title": "Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Soft Tissue Sarcoma Adult"
      ],
      "interventions": [
        {
          "name": "Multiple drug microinjection",
          "type": "DRUG"
        },
        {
          "name": "CIVO device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Presage Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2016-12-15",
      "completion_date": "2021-09-22",
      "has_results": false,
      "last_update_posted_date": "2021-09-24",
      "last_synced_at": "2026-07-22T18:34:37.644Z",
      "location_count": 3,
      "location_summary": "Lake Success, New York • Portland, Oregon • Seattle, Washington",
      "locations": [
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03056599"
    },
    {
      "nct_id": "NCT01831505",
      "title": "Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Presage Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2012-11",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2017-02-27",
      "last_synced_at": "2026-07-22T18:34:37.644Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01831505"
    }
  ]
}